Appendix 4D and Half-year Financial Report
Released
Released
Announcement PDF
Avecho Biotechnology Limited
Appendix 4D
Half-year report
1. Company details
Name of entity:
ABN:
Reporting period:
Previous period:
Avecho Biotechnology Limited
32 056 482 403
For the period ended 30 June 2023
For the period ended 30 June 2022
2. Results for announcement to the market
$
Revenues from ordinary activities
down
41.1% to
446,439
Loss from ordinary activities after tax attributable to the owners of
Avecho Biotechnology Limited
up
173.6% to
(2,127,514)
Loss for the period attributable to the owners of Avecho Biotechnology
Limited
up
173.6% to
(2,127,514)
Comments
Total revenue decreased by 41% for the period to $446,439 (30 June 2022: $758,239), mainly attributable to a decrease
in Vital ET® sales made to Ashland during the period.
Research and development tax incentive and other income increased by 32% to $402,853 (Half-year to 30 June 2022:
$306,346), largely attributed to higher R&D tax incentives of $379,986 (Half-year to 30 June 2022: $254,032).
Expenses from continuing operations increased by 74% to $2,848,496 (Half-year to 30 June 2022: $1,641,162), largely due
to higher research and development cost of $1,111,026 (Half-year to 30 June 2022: $476,166) and administrative expenses
of $1,729,901 (30 June 2022: $1,161,335). Overall increase in the research and development activities compared to the
2022 financial period was as the Company moved into Phase-III trial designed to test the Company’s proprietary CBD softgel capsule for the treatment of insomnia during the period.
At 30 June 2023, the Consolidated Entity held $2,868,346 in cash and cash equivalents (31 December 2022: $1,468,210).
The net assets of the Consolidated Entity decreased by $230,038 to $2,194,858 as at Half-year to 30 June 2023 (31
December 2022: $2,424,896). Working capital, being current assets less current liabilities, was a surplus of $1,942,241 (31
December 2022: $2,105,685).
The net operating cash outflow for the period was $400,397 (30 June 2022: outflow $47,598).
3. Net tangible assets
Reporting
period
Cents
Net tangible assets per ordinary security
4. Control gained over entities
Not applicable.
5. Loss of control over entities
Not applicable.
0.10
Previous
period
Cents
0.13
Avecho Biotechnology Limited
Appendix 4D
Half-year report
6. Dividends
Current period
There were no dividends paid, recommended or declared during the current financial period.
Previous period
There were no dividends paid, recommended or declared during the previous financial period.
7. Dividend reinvestment plans
Not applicable.
8. Details of associates and joint venture entities
Not applicable.
9. Foreign entities
Details of origin of accounting standards used in compiling the report:
Not applicable.
10. Audit status
The financial statements were subject to a review by the auditors and the review report is attached as part of the Half Year
Report.
11. Attachments
Details of attachments (if any):
The Half Year Report of Avecho Biotechnology Limited for the period ended 30 June 2023 is attached.
12. Signed
Signed ___________________________
Dr Gregory Collier
Chairman
Date: 31 August 2023
Avecho Biotechnology Limited
ABN 32 056 482 403
Half Year Report - 30 June 2023
Avecho Biotechnology Limited
Contents
30 June 2023
Corporate directory
Directors' report
Auditor's independence declaration
Consolidated statement of profit or loss and other comprehensive income
Consolidated statement of financial position
Consolidated statement of changes in equity
Consolidated statement of cash flows
Notes to the consolidated financial statements
Directors' declaration
Independent auditor's review report to the members of Avecho Biotechnology Limited
1
2
3
6
7
8
9
10
11
18
19
Avecho Biotechnology Limited
Corporate directory
30 June 2023
Directors
Dr Gregory Collier (Chairman)
Dr Ross Murdoch (Non-Executive Director)
Mr Matthew McNamara (Non-Executive Director)
Chief Executive Officer
Dr Paul Gavin
Company Secretary
Ms Melanie Leydin
Registered office
and Principal place of business
Unit A8, 2A Westall Road
Clayton VIC 3168
Australia
Telephone: +61 3 9002 5000
Email: info@avecho.com.au
Share register
Computershare Investor Services Pty Limited
Yarra Falls, 452 Johnston Street
Abbotsford VIC 3067
Australia
Telephone: +61 3 9415 5000
Fax: +61 3 9473 2500
Auditor
Grant Thornton Audit Pty Ltd
Collins Square Tower 5
727 Collins Street
Melbourne VIC 3008
Stock exchange listing
Avecho Biotechnology Limited securities are listed on the Australian Securities
Exchange. (ASX code: AVE)
Website
www.avecho.com.au
2
Avecho Biotechnology Limited
Directors' report
30 June 2023
The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as
the 'Consolidated Entity') consisting of Avecho Biotechnology Limited (referred to hereafter as the 'Company' or 'parent
entity') and the entities it controlled at the end of, or during, the period ended 30 June 2023.
Directors
The following persons were directors of Avecho Biotechnology Limited during the whole of the financial period and up to the
date of this report, unless otherwise stated:
Dr Greg Collier (Chairman)
Dr Ross Murdoch (Non-Executive Director)
Mr Matthew McNamara (Non-Executive Director)
Principal activities
Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products using its
proprietary drug delivery system called TPM® (Tocopherol Phosphate Mixture). TPM® is derived from Vitamin E using
unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal
absorption of drugs and nutrients.
The Consolidated Entity’s major projects include delivering TPM® enhanced injectable, oral and topical products for the
human health market, including the recently announced application of TPM® to cannabinoids. The Company is also
developing TPM® to enhance feed efficiency and health of livestock.
Review of operations
Capital raising to fund Phase III Clinical Trial for CBD Soft-Gel Capsule
On 10 May 2023, Avecho completed a non-renounceable entitlement offer of one (1) fully paid ordinary share (New Share)
for every 1 existing share held by eligible shareholders at an issue price of $0.006 per Share, raising an amount of
approximately $2 million.
Subsequent to the period ended, on the 28 August 2023, Avecho announced it had received firm commitments from
sophisticated and institutional investors to raise $6 million by way of a placement, which is expected to be completed in two
separate tranches;
●
Tranche 1 will be for 536,803,333 fully paid ordinary shares at an issue price of $0.006 per Share to raise approximately
$3.22 million (before transaction costs), which is expected to be completed on or about 1 September 2023: and
●
Tranche 2 to raise approximately $2.82 million (before transaction costs), will be subject to shareholder approval at a
general meeting, currently expected to be held in or around October 2023 (indicative date subject to change).
Avecho commences CBD soft-gel manufacturing for pivotal Phase III Clinical Trial
At the conclusion of the Entitlement Offer, Avecho commenced manufacturing activities to support its pivotal Phase III Clinical
Trial with a US-based Contract Manufacturing Organisation (“CMO”), Procaps Group.
Procaps Group (NASDAQ: PROC) is a reputable developer of pharmaceutical and nutraceutical solutions, medicines, and
hospital supplies across 50 countries globally. Procaps Group has experience in the manufacture of pharmaceutical
cannabinoid products and is currently manufacturing US Food and Drug Administration (“FDA”) approved dronabinol
synthetic tetrahydrocannabinol (“THC”) capsules for sale in the USA.
Work undertaken by Procaps Group will include the manufacture of three registration batches of Avecho’s CBD capsule.
These batches will be placed on formal stability studies to define shelf life of the commercial product. Initial batches of the
CBD soft-gel capsule have now successfully passed a two-year stability milestone, indicating it meets pharmaceutical
standards. Documentation from these batches is a key component of the registration package to be submitted to regulatory
agencies such as the TGA and FDA.
Clinical supply from the Procaps Group will be available in Q3 2023.
3
Avecho Biotechnology Limited
Directors' report
30 June 2023
TPM business development agreements
In December 2022, Avecho announced a development agreement with NYSE-listed global consumer packaged goods
business Perrigo Company plc (NYSE: PRGO), in a deal that will focus on development of a topical TPM®-enhanced
ibuprofen gel for the US market. Perrigo is planning to conduct a clinical trial in a pain-related indication using the ibuprofen
TPM® gel in 2023. Avecho is managing the manufacture of the Ibuprofen TPM® product in Australia using a third party GMP
contract manufacturer.
In January 2023, Avecho announced that New York-based global biopharmaceutical company Athenex had submitted
Avecho’s TPM®-enhanced phytonadione injectable product to the FDA for feedback via a pre-IND meeting request. Formal
FDA feedback stated that the existing toxicology package demonstrating the safety of TPM appeared sufficient to support
the use of the TPM in a phytonadione injection – although toxicology reports would need to be examined in more detail to
confirm adequacy upon submission of an IND application. Injectable products maker, Sagent Pharmaceuticals, purchased
Athenex’s injectable assets in June after Athenex attempted to spin-out their injectable business. Once the acquisition is
formally concluded, Avecho will determine whether the TPM injectable phytonadione asset remains of interest to Sagent.
In February 2023, Avecho announced its collaboration with the Lambert Initiative would expand beyond the topical
cannabinoid products. While Avecho focuses its efforts on its pivotal Phase III clinical trial testing its CBD soft-gel capsule in
an insomnia indication, the Lambert Initiative trials will test its oral CBD product on a series of novel candidate indications
not previously associated with CBD therapy. These candidate indications have emerged from pre-clinical and early-stage
clinical studies conducted by Lambert Initiative researchers and their colleagues, and represent attractive indications for
future CBD products registered as over-the-counter (OTC) medicines with the Therapeutic Goods Administration (TGA).
In May 2023, Avecho secured a licensing and development agreement with Arthur Group to produce a series of optimised
cancer drugs solubilised using TPM. Under the terms of the agreement, Arthur Group will pay for all formulation, non-clinical
and clinical development of the products – and Avecho will receive 30% of revenue from licensing and 30% of net profit from
commercialisation of these products.
Expanding cannabinoid portfolio
In June 2023, Avecho announced it has completed the development of first generation TPM gummies containing
cannabinoids. Gummies are chewable, jelly-like preparations made from a mixture of glycerin and gelatin and can incorporate
a range of medications or nutraceutical ingredients. With the inclusion of edibles, Avecho’s current cannabinoid portfolio now
contains four different dosage forms with increased absorption – oral oils, oral soft-gel capsules, oral edibles and topical
gels.
Review of financial results
The loss for the Consolidated Entity after providing for income tax for period amounted to $2,127,514 (Half-year to 30 June
2022: loss of $777,674).
●
Total revenue decreased by 41% for the period to $446,439 (Half-year to 30 June 2022: $758,239), mainly attributable
to a decrease in Vital ET® sales made to Ashland during the period.
●
Research and development tax incentive and other income increased by 32% to $402,853 (Half-year to 30 June 2022:
$306,346), largely attributed to R&D tax incentives of $379,986 (Half-year to 30 June 2022: $254,032).
●
Expenses from continuing operations increased by 74% to $2,848,496 (Half-year to 30 June 2022: $1,641,162), largely
due to higher research and development cost of $1,111,026 (Half-year to 30 June 2022: $476,166) and administration
expenses of $1,729,901 (30 June 2022: $1,161,335).
As at 30 June 2023, the Consolidated Entity held $2,868,346 in cash and cash equivalents (31 December 2022: $1,468,210).
The net assets of the Consolidated Entity decreased by $230,038 to $2,194,858 as at 30 June 2023 (31 December 2022:
$2,424,896). Working capital, being current assets less current liabilities, was a surplus of $1,942,241 (31 December 2022:
$2,105,685).
The net operating cash outflow for the period was $400,397 (Half-year to 30 June 2022: outflow $47,598).
4
Avecho Biotechnology Limited
Directors' report
30 June 2023
Significant changes in the state of affairs
On 9 May 2023 the Company completed non-renounceable entitlement offer of 1 new fully paid ordinary share (New Share)
for every 1 existing share held by eligible shareholders at an issue price of $0.006 per New Share as announced to ASX on
3 April 2023 (Entitlement Offer). Participants in the Entitlement Offer were also entitled to 3 free attaching options, with an
exercise price of $0.012 each and expiring 3 years from their issue date (New Options) for every 2 New Shares subscribed
under the Entitlement Offer.
The Entitlement Offer was closed 3 May 2023 with applications were received for 324,289,814 New Shares, raising an
amount of approximately $2 million. On 10 May 2023, the Company completed issuing of 324,289,814 New Shares and
486,434,641 New Options to participating eligible shareholders.
There were no other significant changes in the state of affairs of the Consolidated Entity during the financial period.
Matters subsequent to the end of the financial period
Subsequent to the period ended, on the 28 August 2023, the Company announced it had received firm commitments from
sophisticated and institutional investors to raise $6 million by way of a placement("Placement"). The Placement will be
conducted on the same terms as the Company’s recent Entitlement Offer announced to ASX on 3 April 2023. The $6 million
Placement will be completed in two separate tranches;
●
●
Tranche 1 will be for approximately 536,803,333 fully paid ordinary shares (subject to rounding) at an issue price of
$0.006 per Share to raise approximately $3.22 million (before transaction costs), which is expected to be completed on
or about 1 September 2023; and
Tranche 2 to raise approximately $2.82 million (before transaction costs), will be subject to shareholder approval at a
general meeting, currently expected to be held in or around late October 2023 (indicative date subject to change).
Every two new shares issued under the Placement will be accompanied by three free attaching options, exercisable at $0.012
each, expiring on 10 May 2026.
No other matter or circumstance has arisen since 30 June 2023 that has significantly affected, or may significantly affect the
Consolidated Entity's operations, the results of those operations, or the Consolidated Entity's state of affairs in future financial
years.
Auditor's independence declaration
A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out
immediately after this directors' report.
This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.
On behalf of the directors
___________________________
Dr Gregory Collier
Chairman
31 August 2023
5
Grant Thornton Audit Pty Ltd
Level 22 Tower 5
Collins Square
727 Collins Street
Melbourne VIC 3008
GPO Box 4736
Melbourne VIC 3001
T +61 3 8320 2222
Auditor’s Independence Declaration
To the Directors of Avecho Biotechnology Limited
In accordance with the requirements of section 307C of the Corporations Act 2001, as lead auditor for the review
of Avecho Biotechnology Limited for the half-year ended 30 June 2023, I declare that, to the best of my
knowledge and belief, there have been:
a
no contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the
review; and
b
no contraventions of any applicable code of professional conduct in relation to the review.
Grant Thornton Audit Pty Ltd
Chartered Accountants
J D Vasiliou
Partner – Audit & Assurance
Melbourne, 31 August 2023
www.grantthornton.com.au
ACN-130 913 594
Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389.
‘Grant Thornton’ refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or
refers to one or more member firms, as the context requires. Grant Thornton Australia Limited is a member firm of Grant Thornton International Ltd (GTIL).
GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member
firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one
another’s acts or omissions. In the Australian context only, the use of the term ‘Grant Thornton’ may refer to Grant Thornton Australia Limited ABN 41 127
556 389 ACN 127 556 389 and its Australian subsidiaries and related entities. Liability limited by a scheme approved under Professional Standards
Legislation.
w
Avecho Biotechnology Limited
Consolidated statement of profit or loss and other comprehensive income
For the period ended 30 June 2023
Note
Revenue from contracts with customers
Cost of sales
4
Gross profit
Consolidated
Half-year to 30 Half-year to 30
June 2023
June 2022
$
$
446,439
(128,310)
758,239
(201,097)
318,129
557,142
Research and development tax incentive and other income
5
402,853
306,346
Research and development expenses
Administration and corporate expenses
Finance costs
6
7
(1,111,026)
(1,729,901)
(7,569)
(476,166)
(1,161,335)
(3,661)
(2,127,514)
(777,674)
-
-
(2,127,514)
(777,674)
-
-
(2,127,514)
(777,674)
Loss before income tax expense
Income tax expense
Loss after income tax expense for the period attributable to the owners of
Avecho Biotechnology Limited
Other comprehensive income for the period, net of tax
Total comprehensive loss for the period attributable to the owners of
Avecho Biotechnology Limited
Cents
Basic loss per share
Diluted loss per share
12
12
(0.11)
(0.11)
Cents
(0.04)
(0.04)
The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the
accompanying notes
7
Avecho Biotechnology Limited
Consolidated statement of financial position
As at 30 June 2023
Note
Consolidated
31 December
30 June 2023
2022
$
$
Assets
Current assets
Cash and cash equivalents
Trade and other receivables
Inventories
Prepayments
Total current assets
2,868,346
414,196
135,681
113,849
3,532,072
1,468,210
745,994
401,979
235,006
2,851,189
182,808
207,219
390,027
222,038
246,075
26,250
494,363
3,922,099
3,345,552
Current liabilities
Trade and other payables
Lease liabilities
Provisions
Total current liabilities
1,083,995
73,677
432,159
1,589,831
276,415
70,923
398,166
745,504
Non-current liabilities
Lease liabilities
Total non-current liabilities
137,410
137,410
175,152
175,152
Total liabilities
1,727,241
920,656
Net assets
2,194,858
2,424,896
239,364,321
29,062,381
(266,231,844)
237,528,800
29,000,426
(264,104,330)
2,194,858
2,424,896
Non-current assets
Plant and equipment
Right-of-use assets
Intangibles
Total non-current assets
Total assets
Liabilities
Equity
Issued capital
Reserves
Accumulated losses
8
9
Total equity
The above consolidated statement of financial position should be read in conjunction with the accompanying notes
8
Avecho Biotechnology Limited
Consolidated statement of changes in equity
For the period ended 30 June 2023
Issued
capital
$
Consolidated
Balance at 1 January 2022
Accumulated
losses
Total equity
$
$
Reserves
$
237,601,871
29,001,981 (262,067,262)
4,536,590
Loss after income tax expense for the period
Other comprehensive income for the period, net of tax
-
-
(777,674)
-
(777,674)
-
Total comprehensive loss for the period
-
-
(777,674)
(777,674)
25,440
-
92,775
(305,323)
1,989
305,323
-
25,440
92,775
1,989
28,791,422 (262,539,613)
3,879,120
Transactions with owners in their capacity as owners:
Contributions of equity, net of transaction costs
Share-based payments
Transfer of other reserve balance
Contributions received on exercise of options
Balance at 30 June 2022
237,627,311
Issued
capital
$
Consolidated
Balance at 1 January 2023
Accumulated
losses
Total equity
$
$
Reserves
$
237,528,800
29,000,426 (264,104,330)
2,424,896
Loss after income tax expense for the period
Other comprehensive income for the period, net of tax
-
-
(2,127,514)
-
(2,127,514)
-
Total comprehensive loss for the period
-
-
(2,127,514)
(2,127,514)
1,835,521
-
61,955
-
1,835,521
61,955
29,062,381 (266,231,844)
2,194,858
Transactions with owners in their capacity as owners:
Contributions of equity, net of transaction costs (note 8)
Share-based payments
Balance at 30 June 2023
239,364,321
The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes
9
Avecho Biotechnology Limited
Consolidated statement of cash flows
For the period ended 30 June 2023
Note
Cash flows from operating activities
Receipts from customers (inclusive of GST)
Receipt of government grants and subsidy
Payments to suppliers and employees (inclusive of GST)
Consolidated
Half-year to 30 Half-year to 30
June 2023
June 2022
$
$
709,751
687,288
(1,796,153)
763,654
1,028,323
(1,838,702)
Interest received
Interest and other finance costs paid
(399,114)
4,930
(6,213)
(46,725)
299
(1,172)
Net cash used in operating activities
(400,397)
(47,598)
Cash flows from investing activities
Payments for plant and equipment
-
(48,124)
Net cash used in investing activities
-
(48,124)
1,945,793
(110,272)
(34,988)
(39,829)
Net cash from/(used in) financing activities
1,800,533
(39,829)
Net increase/(decrease) in cash and cash equivalents
Cash and cash equivalents at the beginning of the financial period
1,400,136
1,468,210
(135,551)
3,264,764
Cash and cash equivalents at the end of the financial period
2,868,346
3,129,213
Cash flows from financing activities
Proceeds from issue of shares
Share issue transaction costs
Principal and interest element of lease payments
8
8
The above consolidated statement of cash flows should be read in conjunction with the accompanying notes
10
Avecho Biotechnology Limited
Notes to the consolidated financial statements
30 June 2023
Note 1. General information
The financial statements cover Avecho Biotechnology Limited as a consolidated entity consisting of Avecho Biotechnology
Limited and the entities it controlled at the end of, or during, the period. The financial statements are presented in Australian
dollars, which is Avecho Biotechnology Limited's functional and presentation currency.
Avecho Biotechnology Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its
registered office and principal place of business is:
Unit A8, 2A Westall Road
Clayton VIC 3168
Australia
A description of the nature of the Consolidated Entity's operations and its principal activities are included in the directors'
report, which is not part of the financial statements.
The financial statements were authorised for issue, in accordance with a resolution of directors, on 31 August 2023.
Note 2. Significant accounting policies
These general purpose financial statements for the interim half-year reporting period ended 30 June 2023 have been
prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations
Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International
Financial Reporting Standard IAS 34 'Interim Financial Reporting'.
These general purpose financial statements do not include all the notes of the type normally included in annual financial
statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended
31 December 2022 and any public announcements made by the Company during the interim reporting period in accordance
with the continuous disclosure requirements of the Corporations Act 2001.
The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting
period, unless otherwise stated.
Going concern
The 2023 half-year report has been prepared on the going concern basis, which assumes continuity of normal business
activities and the realization of assets and the settlement of liabilities in the ordinary course of business.
The working capital position as at 30 June 2023 of the Consolidated Entity was a surplus of $1,942,241. The Consolidated
Entity made a loss after tax of $2,127,514 and incurred a net operating cash outflows of $400,397. Cash and cash equivalents
as at 30 June 2023 were $2,868,346. The continuing viability of the Consolidated Entity and its ability to continue as a going
concern is dependent upon the Consolidated Entity being successful in its continuing efforts in R&D activities, the Vital ET
sales with Ashland and accessing additional sources of capital to meet the commitments.
To meet the Consolidated Entity’s funding requirements as and when they fall due the Consolidated Entity will need to take
appropriate steps, including a combination of:
●
●
●
Raising capital by one of or a combination of the following: placement of shares, rights issue, share purchase plan, etc;
Potential debt financing of the R&D tax incentive so the Consolidated Entity can receive the money in advance; and
Defer certain R&D expenditure to the future to reduce the cash outflows.
On 10 May 2023, the Company has completed non-renounceable entitlement offer raising approximately $2 million.
Subsequent to the period ended, on the 28 August 2023, the Company announced it had received firm commitments from
sophisticated and institutional investors to raise $6 million by way of a placement("Placement"). The $6 million Placement
will be completed in two separate tranches;
11
Avecho Biotechnology Limited
Notes to the consolidated financial statements
30 June 2023
Note 2. Significant accounting policies (continued)
●
●
Tranche 1 will be for approximately 536,803,333 fully paid ordinary shares (subject to rounding) at an issue price of
$0.006 per Share to raise approximately $3.22 million (before transaction costs), which is expected to be completed on
or about 1 September 2023; and
Tranche 2 to raise approximately $2.82 million (before transaction costs), will be subject to shareholder approval at a
general meeting, currently expected to be held in or around late October 2023 (indicative date subject to change).
The Directors will continue to monitor the ongoing funding requirements of the Consolidated Entity. As a consequence of the
above, the directors believe that, notwithstanding the Consolidated Entity's operating results for the year, the Consolidated
Entity will be able to continue as a going concern and therefore, these financial statements do not include any adjustments
relating to the recoverability and classification of recorded asset amounts, or to the amounts and classification of liabilities
that might be necessary should the Consolidated Entity not continue as a going concern.
New Accounting Standards and Interpretations adopted
The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the
Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period, which had no impact
on the half-year financial report.
Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.
Note 3. Operating segments
Identification of reportable operating segments
The Consolidated Entity is organised into two operating segments based on differences in products and services provided:
Production segment
The Production segment manufactures and sells TPM® and Vital ET® for the use in drug delivery and cosmetic formulations.
Human Health segment
The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches including
conduct of research and development activities.
These operating segments are based on the internal reports that are reviewed and used by the Board of Directors (who are
identified as the Chief Operating Decision Makers ('CODM')) in assessing performance and in determining the allocation of
resources. There is no aggregation of operating segments.
The CODM reviews EBITDA (earnings before interest, tax, depreciation and amortisation). The accounting policies adopted
for internal reporting to the CODM are consistent with those adopted in the financial statements. The information reported to
the CODM is on a monthly basis.
12
Avecho Biotechnology Limited
Notes to the consolidated financial statements
30 June 2023
Note 3. Operating segments (continued)
Operating segment information
Production
$
Consolidated - Half-year to 30 June 2023
Sales, Licences and Royalties
Cost of sales
Interest income
Research and development tax incentive and other income
Research expenses
Employee and directors benefits expenses
Other operating expenses from continuing operations
Depreciation and amortisation
Loss before income tax expense
Income tax expense
Loss after income tax expense
Human
Health
$
Unallocated
$
Total
$
446,439
(128,310)
(30,758)
(376,340)
(26,250)
(115,2
Share your feedback
Discover